Deal completed by Emerge Invest (sell-side advisor)

Saham Group continues its disengagement from the healthcare sector in Morocco. The Holding has just divested another asset from its healthcare portfolio.

After selling two radiology centers as well as the Private Hospital of Marrakech in 2018, the Moroccan group belonging to Moulay Hafid Elalamy has just completed the divestiture of Saham Pharma. Indeed, "SPE Capital Partners (SPE Capital), a private equity firm led by Nabil Triki with offices in Tunisia, Morocco, Egypt and Ivory Coast, has announced the finalization of the acquisition process of Saham Pharma, a Moroccan pharmaceutical company engaged in the manufacturing of antibiotics. Proparco, the private sector financing arm of the French Development Agency (AFD) also participated by acquiring a minority stake in this former subsidiary of Moroccan holding company Saham Group", states Challenges.tn.

It should be noted that this pharmaceutical laboratory was created in 2011 when Saham Group acquired the British company GSK's (GlaxoSmithKline) unit in Morocco, which subsequently became Saham Pharma.

Through this acquisition, SPE Capital Partners makes its second investment in Morocco through its SPE AIF I fund, focused on Africa. "We believe that the Moroccan pharmaceutical sector has strong growth and resilience fundamentals", commented Nabil Triki, Managing Director of private equity firm SPE Capital. Similarly for the French Proparco, which marks its second direct investment in the healthcare sector in Morocco.

Article sources: Challenge.ma